Dr Dooley's research focuses on systemic lupus erythematosus (SLE) with a particular interest in lupus nephritis (LN). She participates in three unique collaborative groups providing rich resources for her research evaluating the longitudinal outcomes of lupus and lupus nephritis:
- The Glomerular Disease Collaborative Network (GDCN) - An early study from this collaboration identified poor renal outcomes among LN patients with African ancestry prompting all subsequent LN clinical trials to be stratified by race.
- The Systemic Lupus International Cooperating Clinics (SLICC) - Comprised of 30 Lupus Centers from around the world, activities to date include contributing to an inception cohort of 1500 lupus patients and published studies on the risk of neurologic involvement, cancer and reproductive outcomes.
- Dr. Dooley is director of the UNC Lupus Clinical Trials Consortium (LCTC) clinic and site principal investigator. The LCTC is a privately funded research organization which includes 20 Lupus Centers in the US focused on developing a national database to advance research on long term outcomes of SLE since 2003.
Dr. Dooley also participates in many clinical trials of new therapies and strategies for the treatment of SLE and LN. She regularly attends, teaches and mentors rheumatology and nephrology residents and fellows in outpatient clinics, the inpatient nephrology and rheumatology consult services at UNC Hospitals, the UNC Kidney Center, and at the UNC Clinical Trials Research Center (CTRC).
In the Clinic: Dr. Dooley participates in 2 clinics: one day a week in Rheumatology clinic focusing on lupus, sjogren’s and vasculitis patients and one day a week in the Nephrology clinic for the Lupus/Vasculitis clinic and precepting and teaching Nephrology fellows about the clinical presentations, diagnosis and management of rheumatic diseases in patients with chronic kidney disease (gout, osteoporosis in transplant patients, bursitis and musculoskeletal pain).
Education: Dr. Dooley teaches medical students, residents and fellows in her clinics, on the Rheumatology Consult service and while attending on the Nephrology Inpatient service. She speaks locally, nationally and internationally about the clinical features, management and longterm outcomes of Systemic Lupus Erythematosus, especially Lupus Nephritis.
Mary Anne Dooley, MD, MPH
Associate Professor of Medicine
2001-Present - Best Doctors in America, Rheumatology and Immunology
Grants and Collaborative Projects
Lupus Clinical Trials Consortium, Inc. (LCTC) IRB# 09-1125 2003 – present
Dooley: PI/Director of UNC Rheumatology site
A Prospective Registry to Study Presentation, Clinical Course, Treatment Patterns, and Outcomes in Patients with Systemic Lupus Erythematosus
Genentech, Inc. IFN4575g 1/28/10 - 12/31/13
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients with Moderately to Severely Active Systemic Lupus Erythematosus
Pfizer, Inc. B0151006 7/8/12 - 12/31/13
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-04236921 in Subjects with Systemic Lupus Erythematosus (SLE)
Immune Tolerance Network ITN034A1 1/01/08 - 4/30/14
A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs. Cyclophosphamide Aline in the Treatment of Lupus Nephritis
Eli Lilly and Company H9B-MC-BCDT 4/11/2011 - 12/31/14
CTRC – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus(SLE)(ILLUMINATE2)
Human Genome Sciences, Inc HGS1006-C1112 1/7/13 - 12/31/14
A Phase 3 / 4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)
Human Genome Sciences, Inc. HGS1006-C1121 1/31/13 - 12/31/14
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis
Biogen Idec, Inc. 211 LE 201 5/3/12 - 12/31/14
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects with Lupus Nephritis
Human Genome Sciences, Inc. HGS1006-C1115 7/13/12 - 12/31/14
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)
Human Genome Sciences, Inc. HGS1006-C1066 (United States) 4/01/09 - 2/18/15
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bä), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol
Eli Lilly and Company H9B-MC-BCDX 11/26/12 - 12/31/18
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)(ILLUMINATE-2)